Neothetics (NEOT) Reports Q4 Loss of $0.14/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Neothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results
March 23, 2017 8:00 AM EDTSAN DIEGO, March 23, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ: NEOT) today provided a business update and reported financial results for the fourth quarter 2016.
We are encouraged by our progress on our Phase 2 proof of concept trial for LIPO-202 in submental fat reduction and continue to expect top-line data in June 2017, said Mr. Jeffrey M. Nugent, a member of Neothetics Operating Committee and Board of Directors. We remain excited about the submental fat reduction market and continue to believe LIPO-202 will have significant impact on this market. The American Society of Dermatologic Surgeons (ASDS) 2016... More
